Clinical Trials Logo

SCA7 clinical trials

View clinical trials related to SCA7.

Filter by:
  • None
  • Page 1

NCT ID: NCT03660917 Not yet recruiting - SCA7 Clinical Trials

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Start date: January 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.